Allogene Therapeutics: Pay

Allogene Therapeutics paid CEO David Chang, M.D., Ph.D. $14.8M in FY2022 (Dec). No other named executive of that year is on file.

Pay$100 in the stock at the end of FY20 → $25
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

David Chang, M.D., Ph.D.President and Chief Executive Officer
FY2022 (Dec)
FY2021 (Dec)
2 years

CEO pay against the pay peers

In FY2025 (Dec), the median CEO pay of the 12 peers with pay on file was $4.7M. CEO pay of Allogene Therapeutics for that year is not on file.

  1. 1Vir Biotechnology
  2. 2Nurix Therapeutics
  3. 3Beam Therapeutics
  4. 4Agios Pharmaceuticals
  5. 5Precigen
  6. 6Cullinan Therapeutics
  7. 7Lyell Immunopharma
  8. 8Replimune Group
  9. 9Nkarta
  10. 10C4 Therapeutics
  11. 11Editas Medicine
  12. 12Fate Therapeutics
  13. 13Allogene TherapeuticsNot disclosed
  14. 14CARGO Therapeutics, Inc.Not disclosed
  15. 15Cabaletta BioNot disclosed
  16. 16Caribou BiosciencesNot disclosed
  17. 17Foghorn TherapeuticsNot disclosed
  18. 18IGM Biosciences, Inc.Not disclosed
  19. 19Sana BiotechnologyNot disclosed
  20. 20XencorNot disclosed
  21. 21iTeos Therapeutics, Inc.Not disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.